首页> 外文期刊>Systematic Reviews >The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials
【24h】

The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials

机译:儿童和青少年注意缺陷多动障碍的药物和非药物治疗:随机对照试验的系统评价和网络荟萃分析的方案

获取原文
           

摘要

Background Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders of children and adolescents, with a significant impact on health services and the community in terms of economic and social burdens. The objective of this systematic review will be to evaluate the comparative efficacy and safety of pharmacological and non-pharmacological treatments in children and adolescents with ADHD. Methods Searches involving PubMed/MEDLINE and the Cochrane Database of Systematic Reviews will be used to identify related systematic reviews and relevant randomized trials. Search results will be supplemented by reports from the regulatory and health technology agencies, clinical trials registers and by data requested from trialists and/or pharmaceutical companies. We will consider studies evaluating pharmacological interventions (e.g. stimulants, non-stimulants, antidepressants), psychological interventions (e.g. behavioural interventions, cognitive training and neurofeedback) and complementary and alternative medicine interventions (e.g. dietary interventions, supplement with fatty acids, vitamins, minerals, aminoacids, herbal treatment, homeopathy, and mind-body interventions including massage, chiropractic, acupuncture, yoga, meditation, Tai chi). Eligible control conditions will be placebo, waitlist, no treatment and usual care. Randomized controlled trials of a minimum of 3?weeks duration will be included. The primary outcomes of interest will be the proportion of patients who responded to treatment and who dropped out of the allocated treatment, respectively. Secondary outcomes will include treatment discontinuation due to adverse events, as well as the occurrences of serious adverse events and specific adverse events (decreased weight, anorexia, insomnia and sleep disturbances, anxiety, syncope and cardiovascular events). Two reviewers will independently screen references identified by the literature search, as well as potentially relevant full-text articles in duplicate. Data will be abstracted and risk of bias will be appraised by two team members independently. Conflicts at all levels of screening and abstraction will be resolved through discussion. Random-effects pairwise meta-analyses and Bayesian network meta-analyses will be conducted where appropriate. Discussion This systematic review and network meta-analysis will compare the efficacy and safety of treatments used for ADHD in children and adolescents. The findings will assist patients, clinicians and healthcare providers to make evidence-based decisions regarding treatment selection. Systematic review registration PROSPERO CRD42014015008 webcite .
机译:背景技术注意缺陷多动障碍(ADHD)是儿童和青少年最常见的神经发育障碍之一,就经济和社会负担而言,对健康服务和社区产生重大影响。这项系统评价的目的是评估在多动症儿童和青少年中药物和非药物治疗的相对疗效和安全性。方法涉及PubMed / MEDLINE和Cochrane系统评价数据库的检索将用于识别相关的系统评价和相关的随机试验。监管和卫生技术机构的报告,临床试验注册簿以及试验者和/或制药公司要求的数据将补充搜索结果。我们将考虑评估药物干预措施(例如兴奋剂,非兴奋剂,抗抑郁药),心理干预措施(例如行为干预,认知训练和神经反馈)以及补充和替代医学干预措施(例如饮食干预,补充脂肪酸,维生素,矿物质,氨基酸,草药治疗,顺势疗法和身心干预措施,包括按摩,捏脊,针灸,瑜伽,冥想,太极拳)。符合条件的控制条件包括安慰剂,候补名单,无治疗和常规护理。包括至少持续3周的随机对照试验。感兴趣的主要结果将分别是对治疗有反应和退出分配治疗的患者比例。次要结果将包括因不良事件以及严重不良事件和特定不良事件(体重减轻,厌食,失眠和睡眠障碍,焦虑,晕厥和心血管事件)的发生而终止治疗。两名审稿人将独立筛选通过文献检索确定的参考文献,以及可能重复的潜在相关全文文章。数据将被抽象出来,并且有偏见的风险将由两名团队成员分别进行评估。通过讨论解决所有筛选和抽象级别的冲突。适当时将进行随机效应成对荟萃分析和贝叶斯网络荟萃分析。讨论该系统评价和网络荟萃分析将比较儿童和青少年多动症治疗的疗效和安全性。这些发现将帮助患者,临床医生和医疗保健提供者做出有关治疗选择的循证决策。系统审查注册PROSPERO CRD42014015008网站。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号